Citius Pharmaceuticals (NASDAQ:CTXR) Announces Earnings Results

Posted by Brian Himes on May 17th, 2026

Citius Pharmaceuticals (NASDAQ:CTXR – Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of $0.39 by ($1.34), FiscalAI reports. The business had revenue of $1.67 million during the quarter, compared to analyst estimates of $18.79 million.

Citius Pharmaceuticals Stock Performance

Shares of NASDAQ CTXR traded down $0.02 during mid-day trading on Friday, hitting $0.70. 516,793 shares of the stock traded hands, compared to its average volume of 1,069,212. Citius Pharmaceuticals has a 52 week low of $0.57 and a 52 week high of $2.48. The company has a market cap of $15.67 million, a price-to-earnings ratio of -0.29 and a beta of 1.05. The stock has a fifty day moving average price of $0.79 and a 200-day moving average price of $0.92.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on CTXR shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research note on Friday, March 27th. D. Boral Capital reiterated a “buy” rating and issued a $6.00 price objective on shares of Citius Pharmaceuticals in a research report on Wednesday, March 11th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $6.00.

View Our Latest Stock Analysis on CTXR

Institutional Investors Weigh In On Citius Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd boosted its holdings in Citius Pharmaceuticals by 572.8% in the fourth quarter. XTX Topco Ltd now owns 107,118 shares of the company’s stock worth $83,000 after acquiring an additional 91,196 shares in the last quarter. Heights Capital Management Inc. bought a new stake in Citius Pharmaceuticals in the fourth quarter worth $622,000. Asset Advisory Group Inc. bought a new stake in Citius Pharmaceuticals in the fourth quarter worth $46,000. Finally, NewEdge Advisors LLC bought a new stake in Citius Pharmaceuticals in the second quarter worth $40,000. 16.88% of the stock is owned by institutional investors.

About Citius Pharmaceuticals

(Get Free Report)

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.